NASDAQ
4.66USD
-0.12 (-2.51%)
We have scored 7 news catalysts on OmniAb, Inc. (OABI) over the past 12 months. The biggest single-day move next to one of them came Apr 24, 2026, when OABI closed −6.4%: “OmniAb to Participate in Three Upcoming Investor Conferences”. Coverage across the window leans positive (average ticker sentiment +0.37). Most of the impact sits in institutional appeal and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
677.5M
P/E
—
EPS
—
Beta
1.05
52W range
1.3-5.43
Day range
4.51–4.73
Open
4.70
Prev close
4.78
Volume
1.3M
Avg volume
1.3M
Dividend
0.00
IPO
2021-09-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about OmniAb, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for OABI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
